Nintedanib Medicine 06 June 2023 Extended indication Treatment of non-small cell lung cancer (NSCLC) Therapeutic value No estimate possible yet Total cost Registration phase Registration application pending Product Active substance Nintedanib Domain Oncology Reason of inclusion Generic G Main indication Lung cancer Extended indication Treatment of non-small cell lung cancer (NSCLC) Current proprietary name Ofev Already available biosimilars / generics Proprietary name Manufacturer Boehringer Ingelheim Portfolio holder Mechanism of action Tyrosine kinase inhibitor Route of administration Oral Therapeutical formulation Capsule Budgetting framework Intermural (MSZ) Centre of expertise ILD expertisecentrum St. Antoniusziekenhuis Nieuwegein, EMC Rotterdam, OLVG Amsterdam Additional remarks Registration Registration route Centralised (EMA) Type of trajectory Normal trajectory Particularity Unknown ATMP No Submission date December 2022 Expected Registration February 2024 Orphan drug Unknown Registration phase Registration application pending Reimbursement Medicine sluice Additional remarks Het SPC met nummer 300725 verloopt op 8 oktober 2025 Therapeutic value Current treatment options Therapeutic value No estimate possible yet This assessment does not indicate any potential inclusion in the package. Substantiation Duration of treatment Frequency of administration Dosage per administration References Additional remarks Expected patient volume per year Patient volume Market share is generally not included unless otherwise stated. Maximum patient volume for sluice References Additional remarks Expected cost per patient per year Cost References Additional remarks Potential total cost per year Total cost Total cost for sluice Additional remarks Off label use Off label use Unknown Indications off label use References Additional remarks Indication extension Indication extensions Unknown Indication extensions References Additional remarks Other information Additional remarks